Dr Reddy's anticipates recovery with semaglutide launch

Dr Reddy's Laboratories expects a gradual recovery in the current fiscal year after a profit decline last year. Growth in India, Europe, and emerging markets is offsetting pressures in the US business. New product launches and margin improvements are set to support expansion.

The company reported a drop in net profit for the previous fiscal year, primarily due to challenges in its US operations. In contrast, businesses in India, Europe, and emerging markets have demonstrated healthy growth momentum. Officials highlighted that these regions continue to perform well amid the broader recovery efforts.

Relaterte artikler

Elderly woman with type 2 diabetes walking healthily outdoors, holding semaglutide pen, with subtle ENDO 2026 study charts in background
Bilde generert av AI

Study presented at ENDO 2026 links semaglutide to fewer fractures in people with type 2 diabetes

Rapportert av AI Bilde generert av AI Faktasjekket

Semaglutide was associated with a lower rate of bone fractures and greater reductions in body mass index among adults with type 2 diabetes, according to a retrospective analysis presented at the Endocrine Society’s ENDO 2026 meeting in Chicago.

Sun Pharmaceutical Industries posted robust revenue and profit increases for the March quarter. The company noted pressure on EBITDA margins due to higher investments and reduced milestone income. Outlook for the next fiscal year points to steady but moderated expansion.

Rapportert av AI

Danish drugmaker Novo Nordisk is taking a local compounding pharmacy to court in Pretoria to stop the sale of unregistered semaglutide products. The High Court application targets iDexis over patient safety concerns.

Corporate India posted robust revenue increases during the March 2026 quarter. However, rising input costs and a weaker rupee pressured operating margins across many companies.

Rapportert av AI

Market expert Sunil Subramaniam has advised caution for investors amid geopolitical uncertainty and rising input costs. He highlighted consumer durables, capital goods and public sector banks as preferred sectors.

Following its 2025 results showing a 45.4% profit drop due to agribusiness delinquency, Banco do Brasil executives at the BB Day event forecast a 'W'-shaped recovery for the sector in 2026. The payments index is expected to reach 95%, with delinquency pressuring results into mid-year amid risks like Middle East tensions and El Niño. The bank will maintain risk-calibrated lending with stronger guarantees.

Rapportert av AI

India's FMCG sector has posted a subdued performance in 2026, with the index down 10 percent year to date. Several leading companies have recorded double-digit declines amid geopolitical tensions and inflation.

 

 

 

Dette nettstedet bruker informasjonskapsler

Vi bruker informasjonskapsler for analyse for å forbedre nettstedet vårt. Les vår personvernerklæring for mer informasjon.
Avvis